Valuation: Tengion, Inc.

Market Cap 110K 98.43K 90.71K 82.38K 156K 10.29M 160K 1.09M 433K 5.51M 412K 403K 17.43M P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 5.55M 4.98M 4.59M 4.17M 7.89M 521M 8.11M 54.94M 21.89M 279M 20.84M 20.39M 882M EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0.02
10 years 0
Extreme 1.0E-6
0.04
Change 5-day change 1-year change 3-year change Capi.($)
+900.00%-.--% - - 402
-1.06%+9.92%+59.12%+68.61% 68.32B
+1.30%+7.26%+14.63%+90.00% 60.26B
+0.18%-0.03%+19.61%+97.02% 55.86B
-0.88%+11.02%+22.05%+110.93% 48.43B
+1.62%+5.77%+27.67%+44.06% 45.34B
-4.52%-6.13%+192.53%+853.97% 41.76B
+1.97%+9.00%+25.20%+50.98% 34.5B
-0.87%-0.67%+85.20%+57.40% 33.8B
-1.49%+13.52%+43.09%+0.06% 25.96B
Average +89.61%+3.86%+54.35%+152.56% 41B
Weighted average by Cap. -0.37%+4.03%+51.29%+150.30%

Financials

2012 2013
Net sales - -
Net income -16.93M -15.18M -13.99M -12.71M -24.05M -1.59B -24.72M -168M -66.75M -850M -63.53M -62.19M -2.69B -18.93M -16.97M -15.64M -14.21M -26.89M -1.77B -27.64M -187M -74.63M -951M -71.03M -69.52M -3.01B
Net Debt 3.73M 3.35M 3.09M 2.8M 5.3M 350M 5.45M 36.94M 14.72M 188M 14.01M 13.71M 593M 5.44M 4.88M 4.5M 4.08M 7.73M 510M 7.95M 53.85M 21.46M 273M 20.42M 19.99M 864M
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
26
  1. Stock Market
  2. Stocks
  3. TNGNQ Stock